Xarelto No. 1, Prazaxa Ranks 2nd in Call Frequency in HP Market: Rep Track April Survey

According to Anterio Inc.’s Rep Track Survey, which investigates the recollections of doctors of drug detailing activities, the direct Factor Xa inhibitor Xarelto (rivaroxaban) from Bayer Yakuhin ranked first, up from 13th in March, in call frequency in the hospital...read more